Summary
The provided AI claims are largely about probiotics and diarrhea-prevention strategies, but the supplied FDA label excerpts contain no probiotic-specific guidance, contraindications, warnings, dosing instructions, or interaction information to support or assess these claims. Multiple statements are therefore unsupported relative to the provided label text.
Category Scores
Accurate Statements
AUGMENTIN may be taken without regard to meals, but should be taken at the start of a meal to minimize gastrointestinal intolerance and enhance absorption of clavulanate potassium.
Section 2.1 Important Administration Instructions: “may be taken without regard to meals; however… absorption… enhanced when administered at the start of a meal… To minimize… GI intolerance… should be taken at the start of a meal.”
Unsupported Statements
Probiotics are commonly taken alongside Augmentin to help limit antibiotic-related diarrhea.
No probiotic use guidance or statement about probiotics limiting antibiotic-associated diarrhea is present in the supplied label excerpts.
Augmentin disrupts the balance of gut bacteria.
The supplied label discusses alteration of colon flora as a mechanism for C. difficile overgrowth, but does not make a general claim about “disrupting the balance of gut bacteria” or probiotic-directed rationale to limit diarrhea.
Certain probiotic strains can reduce the risk of loose stools without interfering with the antibiotic’s action against infection.
No probiotic efficacy/strain claim and no statement about not interfering with antibiotic action appears in the supplied label excerpts.
Lactobacillus rhamnosus GG is a probiotic strain studied for preventing antibiotic-associated diarrhea.
No probiotic strain information or antibiotic-associated diarrhea prevention claims appear in the supplied label excerpts.
Saccharomyces boulardii is a probiotic strain studied for preventing antibiotic-associated diarrhea.
No probiotic strain information or antibiotic-associated diarrhea prevention claims appear in the supplied label excerpts.
Taking a studied probiotic strain at least two hours apart from each Augmentin dose helps keep the bacteria viable and lets the antibiotic reach therapeutic levels.
No timing/separation instruction for probiotics relative to Augmentin doses appears in the supplied label excerpts.
Spacing probiotic doses by two hours prevents the antibiotic from killing the live probiotic organisms in the gut.
No statement about antibiotics killing live probiotic organisms, nor any probiotic timing guidance, is present in the supplied label excerpts.
A schedule of morning and evening probiotic doses on an empty stomach, separate from Augmentin meals, is a practical schedule most patients follow.
No probiotic dosing schedule, empty-stomach instruction, or assertion about “most patients follow” appears in the supplied label excerpts.
People with severely weakened immune systems should check with a doctor before starting any live-culture product.
No guidance in the supplied label excerpts about live-culture/probiotic products or immune status precautions is present (the label sections provided do not include such information).
In rare cases, probiotics can cause gas or bloating until the gut readjusts.
No probiotic adverse-effect profile (e.g., gas/bloating) appears in the supplied label excerpts.
Starting probiotics only after the last Augmentin pill can still help restore beneficial bacteria.
No probiotic initiation timing guidance or restoration-of-bacteria claim appears in the supplied label excerpts.
Beginning probiotics during Augmentin treatment offers greater protection against diarrhea than starting only after the last dose.
No comparative probiotic timing efficacy statement appears in the supplied label excerpts.
Either starting probiotics during treatment or only after finishing the antibiotic course is safe.
No probiotic safety statement or endorsement of either timing appears in the supplied label excerpts.
The choice of when to start probiotics mainly depends on convenience and symptom severity.
No probiotic counseling guidance is present in the supplied label excerpts.
Many patients finish Augmentin without noticeable digestive trouble.
No general statement about frequency of digestive trouble or probiotic-related outcomes appears in the supplied label excerpts provided.
Contradictions
Important Omissions
Warnings/precautions, contraindications, dosage/administration, and interaction information regarding probiotics/live-culture products relative to AUGMENTIN.
Importance:
High
For any claim about diarrhea prevention: label-supported guidance on C. difficile associated diarrhea (CDAD) recognition, management, and the need to consider CDAD in patients with diarrhea after antibacterial use.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The majority of claims provide probiotic-specific timing, strain, dosing, safety, and mechanism assertions without support from the supplied AUGMENTIN label excerpts. This could mislead readers about evidence-based use and safety relative to the antibiotic, while the supplied label emphasizes that antibiotic-associated diarrhea including CDAD must be considered and managed clinically.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most probiotic-related claims (strain efficacy, dosing/timing offsets, safety, and mechanistic assertions) are not supported by the provided AUGMENTIN FDA label excerpts.
Suggested Improvement
Remove or revise probiotic-specific claims and timing guidance unless the provided label text includes corresponding probiotic/live-culture directions, warnings, contraindications, or interaction statements; instead, rely on the label-supported administration instruction (take at start of meal to minimize GI intolerance) and label warnings about CDAD/monitoring when diarrhea occurs.